TABLE 3.
Characteristics of successfully treated individuals, stratified for therapy type
| Interferon‐cured | DAA‐cured | |
|---|---|---|
| Number | 97 | 102 |
| Age (median, IQR) (years) | ||
| At start of treatment | 37 (28–44) | 49 (41–60) |
| At end of follow‐up | 54 (47–64) | 52 (45–63) |
| HCV infection duration (years) | 29 (23–34) | 45 (38–48) |
| Advanced fibrosis or cirrhosis a | 20 (21%) | 43 (42%) |
| Child–Pugh A/B/C | 18/2/0 | 42/1/0 |
| HCV genotype | ||
| 1 | 36 (37%) | 90 (88%) |
| 2 | 21 (22%) | 2 (2%) |
| 3 | 17 (18%) | 6 (6%) |
| 4 | 1 (1%) | 3 (3%) |
| 5 | 1 (1%) | 0 |
| Unknown | 21 (21%) | 1 (1%) |
| HIV co‐infection | 9 (9%) | 12 (12%) |
| No prior (Peg)‐interferon treatment | 85 (88%) | 61 (60%) |
| History of severe alcohol use b | 9 (9%) | 10 (10%) |
| Body mass index (median, IQR) (kg/m2) | 26 (23–28) | 25 (22–28) |
| Platelet count (median, IQR) | ||
| Prior to successful treatment | 221 (181–271) | 206 (165–254) |
| Two to four year post‐SVR | 234 (195–289) | 228 (185–270) |
| APRI ≥1.0 | ||
| Prior to successful treatment | 20/91 (22%) | 27/102 (27%) |
| Two to four years post‐SVR | 3/80 (4%) | 4/37 (11%) |
| FIB‐4 ≥3.25 | ||
| Prior to successful treatment | 2/91 (2%) | 14/102 (14%) |
| Two to four years post‐SVR | 1/80 (1%) | 4/37 (11%) |
Data are reported as number (percentage) unless otherwise noted. Characteristics reported at the most recent clinical visit, unless otherwise noted. APRI, AST to Platelet Ratio Index; DAA, direct‐acting antivirals; FIB‐4, Fibrosis‐4 Score; HCV, hepatitis C virus; HIV, human immunodeficiency virus; IQR, interquartile range; SVR, sustained virological response.
†Defined as a Fibroscan result ≥9.5 kPa or radiological, histological or clinical diagnosis.
‡Defined as an alcohol intake > 20 units per week.